On December 20, 2021 TTC Oncology ("TTC" or the "Company"), an early-stage biotech company, reported that preparing to enter phase 2 clinical trials, is innovating safer solutions for the treatment of metastatic breast cancer, whose mission is to develop and bring to market a novel, small-molecule therapy to address unmet needs of breast cancer patients, reported the launch of its equity crowdfunding campaign on WeFunder with an initial investment of $100,000 (Press release, TTC Oncology, DEC 20, 2021, View Source [SID1234597494]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are thrilled to be launching this equity crowdfunding campaign, which is providing bridge financing for us as we plan for and fundraise for our phase 2 clinical trial. The trial will include validation of biomarker that would predict benefit from TTC-352 therapy, as well as provide signal of activity versus therapy of physician’s choice," said Arkadiusz (Arek) Z. Dudek, MD, PhD, TTC Oncology’s President and Chief Executive Officer.
Lead investor, Dr. William T. Beck, Distinguished Professor of Pharmacology and Molecular Genetics, University of Illinois at Chicago, stated, "I decided to invest in TTC Oncology because I see the enormous potential of the breast cancer drug being developed by this company."
TTC Oncology has opened an equity crowdfunding campaign on WeFunder as bridge financing to support its larger fundraising effort to further develop its novel therapy targeting estrogen receptor positive metastatic breast cancer after failure of hormonal treatment. Potential investors are invited to visit the WeFunder page for investment details.
Highlights of TTC-352:
TTC previously raised over $6 million to fund its phase 1 clinical trial with humans, which produced encouraging data. This study showed early signs of efficacy with prolonged disease control for up to 309 days;
The drug provides a non-toxic, novel mechanism of action therapy for hormone resistant of breast cancer;
The delivery mechanism is a safe and well tolerated oral capsule therapy ideal for late-stage cancer patients;
The intellectual property is patent protected until 2033;
Exhibits a biomarker that predicts benefit from TTC-352 therapy; and
Provides synergistic activity with PI3K inhibitors.
TTC Oncology plans to present its phase 2 clinical trial plans at the Biotech Showcase, January 10-19 in San Francisco. The Company will be available for virtual presentation should conditions permit. Additionally, the Company will be participating in the BIO partnering event at the 2022 JP Morgan Healthcare Conference.
To schedule a meeting with management, please contact Klara Czobor, Director of Development, TTC Oncology.